medigraphic.com

2005, Number S1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2005; 43 (S1)

Therapeutic plasma exchange for M-protein disorders: Considerations for hyperviscosity and myeloma kidney

Weinstein R

Language: English
References: 27
Page: 159-161
PDF size: 111.76 Kb.


ABSTRACT

Monoclonal immunoglobulins or immunoglobulin fragments that accumulate in the plasma are referred to as M-proteins.1 When the plasma concentration of an M-protein is low (generally ‹ 3.0 gm/dL) and does not rise over time the M-protein is referred to as a monoclonal gammopathy of uncertain significance and the prognosis is generally benign.2 However in certain M-protein disorders, notably multiple myeloma and Waldenström’s macroglobulinemia, the plasma M-protein concentration usually increases and this may result in clinical disease.1,2


REFERENCES

  1. 1. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA 1992;268:2946-2951.

  2. 2. Kyle RA, Vincent Rajkumar S. Monoclonal gammopathies of undetermined significance. Best Pract Res Clin Haematol 2005;18:689-707.

  3. 3. Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglo-bulinemias. Ther Apheresis 2001;5:171-175.

  4. 4. Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apheresis 2002;6:45-52.

  5. 5. Smith JW, Weinstein R, Hillyer KL, for the AABB Hemapheresis Committee. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003;43:820-822.

  6. 6. Weinstein R. Basic principles of therapeutic blood exchange. En: McLeod BC, Price TH, Weinstein R, editors. Apheresis: principles and practice. Second edition. Bethesda, MD: AABB Press; 2003. p. 295-320.

  7. 7. McLeod BC. Introduction to the third special issue: Clinical Applications of therapeutic apheresis. J Clin Apheresis 2000;15:1-5.

  8. 8. Solomon A, Fahey JL. Plasmapheresis therapy in macroglobulinemia. Ann Int Med 1963;58:789-800.

  9. 9. Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med 1979;66:684-688.

  10. Alexanian R. Blood volume in monoclonal gam-mopathy. Blood 1977;49:301-307.

  11. Weinstein R, Mahmood M. Case 6-2002. Case Records of the Massachusetts General Hospital. N Engl J Med 2002;346:603-610.

  12. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. En: Berkman EM, Umlas J, editors. Therapeutic hemapheresis. Washington, DC: American Association of Blood Banks; 1980:13-52.

  13. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J, for the Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma–a demographic study of 1353 patients. Eur J Haematol 1994;53:207-212.

  14. Knudsen LM, Hjorth M, Hippe E, for the Nordic Myeloma Study Group. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 2000;65:175-181.

  15. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL. Medicine 1978;57:161-166.

  16. Levi DF, Williams RC Jr. Lindstrom FD. Immuno-fluorescent studies of themyeloma kidney with special reference to light chain disease. Am J Med 1968;44:922-933.

  17. Oliver J. New directions in renal morphology: a method, its results and its future. Harvey Lect 1945; 40:102-155.

  18. Misiani R, Tiraboschi G, Mingardi G, Mecca G. Management of myeloma kidney: An anti-light-chain approach. Am J Kid Dis 1987;10:28-33.

  19. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Con-trolled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175-1180.

  20. Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retro-spective case series. Am J Nephrol 1999;19:45-50.

  21. Feest TG, Burge PS, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. Br Med J 1976; 1:503-504.

  22. Zucchelli P, Pasquali S, Cagnoli L, Rovinetti C. Plasma exchange therapy in acute renal failure due to light chain myeloma. Trans Am Soc Artif Intern Organs 1984;30:36-39.

  23. Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-869.

  24. Mahmood A, Sodano D, Flanagan J, Dash A, Weinstein R. Tandem plasma exchange and hemo-dialysis reverses myeloma kidney. J Clin Apheresis 2003;18:47a.

  25. Mahmood A, Sodano D, Flanagan J, Dash A, Weinstein R. Therapeutic plasma exchange per-formed in tandem with hemodialysis for patients with M-protein disorders. J Clin Apheresis 2005; manuscript submitted.

  26. Siami GA, Siami FS. Intensive tandem cryofiltration apheresis and hemodialysis to treat a patient with severe calciphylaxis, cryoglobulinemia, and end stage renal disease. ASAIO J 1999;45:229-233.

  27. National Kidney Foundation/Dialysis Outcome Quality initiative clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kid Dis 2001;37 (1 Suppl 1):S7-S64.




2020     |     www.medigraphic.com